Scientists probe immune secrets to boost melanoma drug success
NCT ID NCT02626065
Summary
This study aimed to understand why some patients with advanced skin cancer (metastatic melanoma) respond well to a type of immunotherapy called anti-PD1, while others do not. Researchers closely tracked changes in patients' immune cells before and during treatment. The goal was to find biological clues that could help predict treatment success and guide future strategies to improve response rates.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
Conditions
Explore the condition pages connected to this study.